Our subsidiaries is the key of our business..
Reponex Pharmaceuticals
Our subsidiary company
Reponex Pharmaceuticals A/S is the subsidiary company of Pharma Equity Group. By repositioning Reponex finds new uses for active substances that are being used in other treatments. This means that the substances are used for other treatments than they were originally designated and registered for. The advantage of this is that the active substance’s basic toxicity and adverse effect profile is already known and described.
Repositioning has the potential to affect a significant number of patients, where there is currently an unmet medical need. When repositioned treatments result in an improved efficacy, safety and / or cost saving effect both the patients and the drug developers reap from the benefits. Pharmaceutical companies can save both money and time in the development by streamlining validation studies without the need to repeat human safety studies, giving patients faster access to new treatment paradigms aimed at treating their personal diseases.
Through the innovative reuse of existing knowledge, Reponex seeks to execute its clinical development programs to the fullest possible extent and thereby achieve low project risk. By combining effective drug development strategies, i.e. by repositioning in combination with a new route of administration, and in some cases by combination with various other active substances that act synergically on various aspects of the disease, the developments seek to achieve a potent therapeutic effect.
It is Reponex’s ambition to create value through the company’s sustaining platform by bringing the clinical programs to a clinical-stage with relevant clinical data documenting the effect of the drug candidates, which will be a strong starting point for the completion of an exclusive licensing of the company’s drug candidates to global pharmaceutical companies, that can contribute to the execution of the further clinical and regulatory process as well as having relevant distribution power.
Reponex’s drug development is based on the repositioning of established APIs (active pharmaceutical ingredients) with regard to new indications, new ways of administration, and combination with other APIs. The clinical developments are performed in close collaboration with public research institutions and university hospitals, which in parallel obtain a research and publishing spin-off.
Globale Patenter
Hos Reponex Pharmaceuticals er vores mission at forbedre behandlingen af komplekse sygdomme gennem innovativ forskning og udvikling. Som et resultat af mange års dedikeret indsats har vi opnået globale patenter inden for tre centrale medicinske områder: Peritonitis, Inflammatorisk Tarmsygdom (IBD) og Kolorektal Cancer.
Vores patenter afspejler vores dedikation til at skabe avancerede løsninger, der kan forbedre patienternes livskvalitet og behandlingsmuligheder verden over.
Peritonitis
Peritonitis is a serious inflammatory condition in the abdominal cavity that can be life-threatening if not treated quickly and effectively. Our patented technologies focus on developing new treatment methods that can reduce complications, improve survival rates and shorten hospital stays for patients. We are continuously working to optimize these solutions so that they can be implemented widely and make a difference in clinical practice.
Inflammatorisk Tarmsygdom (IBD)
IBD, including Crohn’s disease and ulcerative colitis, are chronic conditions that can be highly debilitating for those affected. With our patents in this area, we have developed new, targeted therapies aimed at reducing inflammation and protecting the gut lining. Our solutions have the potential to offer patients with IBD a more effective and gentle treatment that can improve their daily lives.
Colorectal Cancer
Colorectal cancer is one of the most common types of cancer worldwide. Our research has led to patents for breakthrough therapies that can target cancer cells while minimizing side effects. We are working intensively to bring these solutions from the laboratory to the clinic so that we can improve treatment outcomes and increase the chances of survival for patients worldwide.
Our Commitment to Future Treatments
With our global patents, Reponex Pharmaceuticals consolidates its position as a leading player in innovative medical research. Our team is dedicated to translating scientific breakthroughs into effective treatments that can improve the lives of patients across borders.
We look forward to continuing our journey with new discoveries and partnerships that can bring next-generation treatment options to patients around the world.